- About Us
- Nano-Social Network
- Nano Consulting
- My Account
April 17th, 2007
Representatives from Merck will make a special presentation to researchers and scientists in universities and companies at the Nanotech 2007 conference on May 23, 2007 at the Santa Clara Convention Center in California.
Merck recently acquired Sirna Therapeutics, a leader in efforts to create RNAi-based therapeutics that could significantly alter the treatment of disease. RNAi-based therapeutics selectively catalyze the destruction of the RNA transcribed from an individual gene enabling an novel approach to discovering drugs with the potential to produce highly specific, potent, and long-lasting effects.
|Related News Press|
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
Strength of hair inspires new materials for body armor January 18th, 2017
Self-assembling particles brighten future of LED lighting January 18th, 2017
Nanoparticle exposure can awaken dormant viruses in the lungs January 17th, 2017
Nanometrics to Present at the 19th Annual Needham Growth Conference December 22nd, 2016